Aarno Palotie
Research Subjects
Aarno Palotie has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Arto Orpana
3 shared publications- Heikki Repo
Department of Bacteriology and Immunology, University of Helsinki, The Haartman Institute, P.O. Box 21, 00014 Helsinki, Finland
2 shared publications Krista Anttonen
2 shared publicationsMarjatta Leirisalo-Repo
2 shared publications- Petri Salven
Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
2 shared publications Ari Ristimäki
Obstetr. Gynecol, University of Helsinki, Helsinki, Finland
1 shared publication
Latest Publications
- 1 January 2002
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 31 (6) , 355-361
CD14 and TNFα promoter polymorphisms in patients with acute arthritis
To examine CD14 and TNFalpha gene polymorphisms in early arthritis in relation to clinical outcome. We studied 141 Caucasians who had had early arthritis 10 to 38 years earlier. We analysed CD14 (-159) and TNFalpha (-238, -308, -376) polymorphisms using a novel cycle minisequencing method. DNA pools from 370 Caucasian blood donors served as controls. CD14 (-159)C-->T allele frequencies were comparable among patients and controls (39% vs 40%). Fifty men and 42 women had recovered while 24 men and six women had chronic spondyloarthropathy (SpA). Mutant T allele frequency was higher in the chronic SpA group than in the recovered group in women (75% vs 32%, relative risk 1.3, 95% confidence limit 1.1 to 1.6, P = 0.011), but not in men (38% vs 44%). All female patients with chronic SpA had CD14 (-159)T allele and none had a possibly protective TNFalpha (-308)G-->A allele. Possession of CD14 (-159)T allele does not increase risk of ReA but may increase susceptibility of female patients to development of chronic SpA.
- 1 January 2002
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 31 (6) , 355-361
CD14 and TNFα promoter polymorphisms in patients with acute arthritis
To examine CD14 and TNFalpha gene polymorphisms in early arthritis in relation to clinical outcome. We studied 141 Caucasians who had had early arthritis 10 to 38 years earlier. We analysed CD14 (-159) and TNFalpha (-238, -308, -376) polymorphisms using a novel cycle minisequencing method. DNA pools from 370 Caucasian blood donors served as controls. CD14 (-159)C-->T allele frequencies were comparable among patients and controls (39% vs 40%). Fifty men and 42 women had recovered while 24 men and six women had chronic spondyloarthropathy (SpA). Mutant T allele frequency was higher in the chronic SpA group than in the recovered group in women (75% vs 32%, relative risk 1.3, 95% confidence limit 1.1 to 1.6, P = 0.011), but not in men (38% vs 44%). All female patients with chronic SpA had CD14 (-159)T allele and none had a possibly protective TNFalpha (-308)G-->A allele. Possession of CD14 (-159)T allele does not increase risk of ReA but may increase susceptibility of female patients to development of chronic SpA.
- 1 January 1998
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 80 (07) , 171-175
Peripheral Blood Platelets Express VEGF-C and VEGF which Are Released during Platelet Activation
Summary: VEGF-C is a recently characterised endothelial growth factor structurally related to vascular endothelial growth factor (VEGF). We studied the expression of VEGF-C and VEGF in the cells of peripheral blood and in the umbilical cord blood CD 34+ cells, representing haematopoietic progenitor cells. Expression of VEGF-C was detected in the CD34+ cells. In peripheral blood VEGF-C mRNA was restricted to platelets and T-cells. In contrast to the expression pattern of VEGF-C, VEGF mRNA was detected in all peripheral blood cell fractions studied, and also in CD34+ cells. VEGF-C mRNA was also detected in fresh bone marrow samples of acute leukaemia patients, but the expression did not show lineage specificity. VEGF-C and VEGF polypeptides were present in platelets and they were released from activated platelets together with the release of β-thromboglobulin, suggesting that VEGF-C and VEGF reside in the α-granules of platelets. VEGF-C and VEGF, released from activated platelets, may have a role in angiogenesis during wound healing, and possibly also in other pathological conditions, such as atherosclerosis, tumour growth, and metastasis formation.
- 1 January 1998
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 80 (07) , 171-175
Peripheral Blood Platelets Express VEGF-C and VEGF which Are Released during Platelet Activation
Summary: VEGF-C is a recently characterised endothelial growth factor structurally related to vascular endothelial growth factor (VEGF). We studied the expression of VEGF-C and VEGF in the cells of peripheral blood and in the umbilical cord blood CD 34+ cells, representing haematopoietic progenitor cells. Expression of VEGF-C was detected in the CD34+ cells. In peripheral blood VEGF-C mRNA was restricted to platelets and T-cells. In contrast to the expression pattern of VEGF-C, VEGF mRNA was detected in all peripheral blood cell fractions studied, and also in CD34+ cells. VEGF-C mRNA was also detected in fresh bone marrow samples of acute leukaemia patients, but the expression did not show lineage specificity. VEGF-C and VEGF polypeptides were present in platelets and they were released from activated platelets together with the release of β-thromboglobulin, suggesting that VEGF-C and VEGF reside in the α-granules of platelets. VEGF-C and VEGF, released from activated platelets, may have a role in angiogenesis during wound healing, and possibly also in other pathological conditions, such as atherosclerosis, tumour growth, and metastasis formation.